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Background: Quality of life (QOL) for patients with coronary heart disease (CHD) is now concerned worldwide with
the specific instruments being seldom and no one developed by the modular approach.
Objectives: This paper is aimed to develop the CHD scale of the system of Quality of Life Instruments for Chronic
Diseases (QLICD-CHD) by the modular approach and validate it by both classical test theory and Generalizability
Theory.
Methods: The QLICD-CHD was developed based on programmed decision procedures with multiple nominal and
focus group discussions, in-depth interview, pre-testing and quantitative statistical procedures. 146 inpatients with
CHD were used to provide the data measuring QOL three times before and after treatments. The psychometric
properties of the scale were evaluated with respect to validity, reliability and responsiveness employing correlation
analysis, factor analyses, multi-trait scaling analysis, t-tests and also G studies and D studies of Genralizability Theory
analysis.
Results: Multi-trait scaling analysis, correlation and factor analyses confirmed good construct validity and criterion-
related validity when using SF-36 as a criterion. The internal consistency α and test-retest reliability coefficients
(Pearson r and Intra-class correlations ICC) for the overall instrument and all domains were higher than 0.70 and
0.80 respectively; The overall and all domains except for social domain had statistically significant changes after
treatments with moderate effect size SRM (standardized response mea) ranging from 0.32 to 0.67. G-coefficients
and index of dependability (Ф coefficients) confirmed the reliability of the scale further with more exact variance
components.
Conclusions: The QLICD-CHD has good validity, reliability, and moderate responsiveness and some highlights, and
can be used as the quality of life instrument for patients with CHD. However, in order to obtain better reliability, the
numbers of items for social domain should be increased or the items’ quality, not quantity, should be improved.
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Coronary heart disease (CHD) is worldwide the leading
cause for morbidity and mortality in adults [1,2]. In
Germany, prevalence rates of CHD in the general popu-
lation are 6.5% (women) to 9.1% (men) [3]. In the United
States, CHD is the number 1 cause of death among
American men and women, causes 1 of every 5 deaths,
and accounted for an estimated $177 billion in direct
and indirect costs in 2010 [4]. On the data from Na-
tional Health and Nutrition Examination Survey 2005 to
2008, an estimated 16300 000 American adults have
CHD, with the CHD prevalence for the total, men and
women which larger than 20 years old being 7.0%, 8.3%
and 6.1%, respectively in the United States [5]. In China,
CHD is the second leading cause of cardiovascular
death, accounted for 22% of cardiovascular deaths in
urban areas and 13% in rural areas [6]. The age-adjusted
CHD mortality among the population aged >35 years in
2004 is 128.0 per 100 000 per year for urban men, 97.8
for urban women and 79.7 for rural men, 57.3 for rural
women, using the new world standard population [6].
An epidemiological study showed that there were about
1,300,000 new cases of CHD diagnosed in China each
year [7], and the incidence of CHD is steadily increasing
in China [8]. It was estimated that three-fourths of
global deaths and 82% of the total disability adjusted life
years lost due to CHD occurred in middle-income
countries [9].
There has been a rapid and significant growth in the
measurement of quality of life as an indicator of health
outcome in patients with CHD, considering that it has
long disease duration and much symptoms and therapy
side effects. According to WHO (World Health Organiza-
tion), Quality of Life (QOL) is defined as individual’s per-
ceptions of their position in life in the context of the
culture and value systems in which they live and in rela-
tion to their goals, expectations, standards and concerns.
It includes aspects of health such as physical functioning,
social and role functioning, mental health, and general
health perceptions that people experience directly. There-
fore, QOL is an increasingly important outcome in the
study of diseases, and a suitable endpoint in cardiac popu-
lations, also in terms of long-term prognosis. In the clin-
ical course of CHD, there are many aspects where
patients’ quality of life may be affected which include
symptoms of angina and heart failure, limited exercise
capacity of the aforementioned symptoms, the physical
debility caused, and psychological stress associated with
the chronic stress. Many studies have demonstrated that
assessing changes in QOL could be a useful complement
to clinical management of CHD by assisting in monitoring
disease severity and progression [10-12]. Although generic
instruments such as the SF-36 and Euroqol EQ-5D were
widely used for evaluating QOL of CHD, they do notcapture symptoms and side effects specific to CHD [13].
Thus, some disease-specific QOL instruments [13-20] for
CHD have been developed including Seattle Angina Ques-
tionnaire (SAQ) [14], Quality of Life after Myocardial In-
farction (QLMI) [15], the MacNew Heart Disease Quality
of Life instrument [16], Minnesota Living with Heart Fail-
ure questionnaire (MLHF) [17], Angina Pectoris Quality
of Life Questionnaire(APQLQ) [18], the Myocardial In-
farction Dimensional Assessment Scale(MIDAS) [19], the
Cardiovascular Limitations and Symptoms Profile (CLASP)
[20], etc. However, these instruments are appropriate for
either angina pectoris or myocardial infarction, and were
not developed by the popular modular approach-a gen-
eral/core module plus specific modules. The modular ap-
proach has the advantages of being developed fast and
easily, and the resulting scale has well-characterized struc-
ture, in which the general module is used to capture the
psychometric properties shared by a group of relevant dis-
eases, while the disease-specific module is used to
characterize the distinctive disease features [21-23]. More-
over, they are lacking Chinese cultural backgrounds to
some extent considering their original use in English-
spoken patients. For example, Taoism and traditional
medicine focus on good temper and high spirit. Good ap-
petite and sleep are highly regarded in daily life with food
culture being very important. This kind of culture depend-
ence does not reflect in most QOL instruments in other
languages.
In respond to this need, we have developed a system
of Quality of Life Instruments for Chronic Diseases
(QLICD, V1.0) by combining a general QOL module
and disease-specific modules under the guides of clas-
sical test theory (CTT) and Generalizability Theory
(GT), Item Response Theory (IRT) [23,24]. The general
module, called QLICD-GM, can be used with all types
of chronic disease patients, while the specific module ad-
dresses the lack of specificity in the general module by
capturing the unique aspects of QOL pertaining to the
specific disease [23,24]. For example, the Hypertension
instrument QLICD-HY is constructed by combining
QLICD-GM with the specific module for Hypertension
[24]. Similarly, the coronary heart disease instrument
(QLICD-CHD) is constructed by combining QLICD-GM
with the specific module for this disease. In this paper,
we describe the developmental process and study the
validation of this QLICD-CHD.
Methods
Establishment of the general module (QLICD-GM)
By following WHO’s definition of QOL [25], a nominal
group consisting of 16 individuals and a focus group
with 10 experts including physicians/nurses and medical
researchers were formed to use the programmed deci-
sion method to present the conceptual framework and
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only on qualitative analysis such as nominal group, focus
group discussions and in-depth interview, but also on
four quantitative statistical procedures—variation pro-
cedure, correlation procedure, factor analysis procedure
and cluster analysis procedure. The entire process of de-
veloping the QLICD-GM has been described in detail
elsewhere [23], but the main steps were summarized as
a schematic diagram below:
Item pool (73 items)
↓ focus and nominal group discussions
Screened refining Items (46 items)
↓ importance test (86 cases interview), analysis, focus
group discussions
Primary scale (V0.0, 38 items)
↓ pre-test (201 cases), analysis, focus group
discussions
Final scale (V1.0, 3 domains, 10 facets, 30 items)
↓ 620 patients
Evaluation (validity, reliability, responsiveness)
The final QLICD-GM included 30 items (selected
from a 73-item pool) which be classified into 3 domains
and 10 facets with physical domain having 8 items
(coded PH1-PH8), psychological domain 11 items
(coded PS1-PS11) and social domain 8 items (coded
SO1-SO8) (see Table 1 for details). This scale was shown
to have good validity, reliability, and better responsive-
ness compared with the SF-36 based on the data from
620 inpatients of seven chronic diseases: hypertension,
coronary heart disease, chronic gastritis, peptic ulcer,
COPD, chronic obstructive lung disease, and chronic
pulmonary heart disease [23].
Establishment of the specific module
After development of the QLICD-GM, twenty-five items
that reflect symptoms, side effects and special mental
health of CHD were selected to form the item pool of
the specific module. A developmental process similar to
the one described above for the general module was
used to obtain the final module, which consists of 16
items, coded CHD1-CHD16, classified into 3 facets (see
Table 1 in detail). Specifically, the symptom (SYM) facet
includes six items of ‘Did you feel short of breath?’
(CHD1), ‘Did you have pain in left shoulder and arm?’
(CHD2), ‘Did you have pain in Upper abdomen?’
(CHD3), ‘Was it last for a long time when your chest
pain/discomfort occurs?’ (CHD4), ‘How often has your
chest pain/discomfort occur?’ (CHD5), ‘How seriously
was it when your chest pain/discomfort occurs?’ (CHD6).
The facet of effect of medicine (EFM) includes one item of
‘Can your chest pain been relieved by rest or taking nitro-
glycerin under the tongue?’ (CHD7). The facet of effect onmental health and daily life (EML) includes nine items of
‘How often have you been worried about chest pain?’
(CHD8), ‘Were you able to control or adjust your negative
emotion?’ (CHD9), ‘Did you feel trouble about taking
medicine for disease?’ (CHD10), ‘Did you feel trouble
about your weight?’ (CHD11), ‘Were you able to adapt to
life style change such as low-salt diet and quit smoking?’
(CHD12), ‘Did your disease make you lack of safety?’
(CHD13), ‘Have you been bothered by sexual problem
caused by disease?’ (CHD14), ‘How much have the activity
limitation cause by your disease affected your life and
work?’ (CHD15), ‘If you had to spend the rest of life with
the symptoms and treatments the way it is right now, can
you accept that optimistically?’ (CHD16).
Validation of the QLICD-CHD
Data collection and scoring
The formal QLICD-CHD (the general module QLICD-
GM plus the specific module) described above was used
for patients with CHD in a field survey in order to study
its psychometric properties (validity, reliability and re-
sponsiveness). The study population was limited to CHD
inpatients who were able to read and understand the
questionnaires at any stages and treatments. The partici-
pating investigators (doctors and medical post-graduate
students) explained the trial and the scale to the patients
and obtained informed consent from those who agreed
to participate in the study. Each patient (n = 146) was
asked to answer the questionnaires at the time of admis-
sion to the hospital by themselves. A random sub-
sample consisting of 50 patients also participated in a
second assessment the following day after hospitalization
so that the test-retest reliability can be calculated. All
patients available at the third scheduled assessment
time-point (111 cases) completed the measures at dis-
charge (after approximately 1 week of treatment) to
evaluate responsiveness of the questionnaire. Answers
were checked immediately each time by the investigators
in order to ensure its integrality. If missing values were
found, the questionnaire would be returned to the pa-
tients to fill in the missing item.
The Chinese version of SF-36 [26], which have eight
domains: Physical Function (PF), Role-Physical (RP),
Bodily Pain (BP), General Health (GH),Vitality (VT), So-
cial Function (SF), Role-Emotional (RE) and Mental-
Health (MH), was also used to provide data for assessing
the criterion-related validity of the QLICD-CHD, and
also convergent and discriminant validity.
Based on the data collected, the raw scores of items,
domains and overall scale were calculated. Each item of
QLICD-CHD is rated in a five-level Likert scoring sys-
tem, namely, not at all, a little bit, somewhat, quite a bit,
and very much. The positively stated items are directly
scored from 1 to 5, while the negatively stated items are
Table 1 Correlation coefficients r among items and domains/facets of QLICD-CHD (n = 146)
Item Physical domain PHD Psychological domain PSD Social domain SOD Specific domain SPD
IND AAS PHS COG ANX DEP SEC SSS SOE SEF SYM EFM EML
PH1 0.64 0.34 0.19 0.52 0.28 0.23 0.11 0.11 0.21 0.41 0.30 0.04 0.50 0.10 0.11 0.12 0.14
PH3 0.88 0.24 0.46 0.73 0.51 0.23 0.24 0.31 0.38 0.11 0.47 0.12 0.35 0.37 0.05 0.15 0.29
PH4 0.85 0.24 0.52 0.75 0.57 0.32 0.30 0.45 0.48 0.05 0.40 0.09 0.27 0.41 0.05 0.21 0.33
PH6 0.28 0.80 0.22 0.50 0.07 0.01 0.07 0.03 0.02 0.26 0.00 0.00 0.20 0.15 0.23 0.01 0.10
PH7 0.29 0.81 0.33 0.55 0.24 0.15 0.01 0.09 0.14 0.09 0.11 0.24 0.09 0.18 0.10 0.06 0.12
PH2 0.32 0.30 0.81 0.62 0.41 0.41 0.46 0.37 0.50 0.06 0.33 0.23 0.20 0.34 0.01 0.23 0.32
PH5 0.30 0.16 0.80 0.56 0.39 0.28 0.34 0.32 0.40 0.06 0.33 0.08 0.18 0.09 0.13 0.07 0.08
PH8 0.54 0.38 0.73 0.72 0.46 0.46 0.24 0.29 0.44 0.12 0.33 0.05 0.30 0.59 0.07 0.32 0.49
PS1 0.54 0.18 0.44 0.53 0.90 0.34 0.31 0.34 0.54 0.04 0.61 0.02 0.34 0.50 0.03 0.32 0.46
PS2 0.48 0.17 0.51 0.52 0.88 0.57 0.50 0.50 0.72 0.03 0.62 0.13 0.39 0.43 0.17 0.46 0.52
PS5 0.25 0.04 0.33 0.29 0.36 0.84 0.64 0.59 0.75 0.05 0.37 0.26 0.25 0.19 0.13 0.44 0.38
PS6 0.31 0.14 0.43 0.39 0.48 0.84 0.51 0.51 0.72 0.03 0.35 0.16 0.23 0.34 0.08 0.48 0.48
PS7 0.27 0.04 0.47 0.35 0.44 0.87 0.52 0.53 0.73 0.01 0.36 0.24 0.26 0.32 0.08 0.49 0.47
PS3 0.29 0.04 0.39 0.31 0.38 0.54 0.91 0.58 0.74 0.07 0.35 0.08 0.29 0.22 0.08 0.30 0.31
PS4 0.31 0.03 0.43 0.36 0.47 0.68 0.90 0.64 0.82 0.09 0.42 0.05 0.34 0.26 0.09 0.37 0.37
PS11 0.13 0.07 0.35 0.19 0.33 0.50 0.83 0.67 0.71 0.06 0.28 0.22 0.17 0.11 0.08 0.43 0.31
PS8 0.17 0.04 0.23 0.20 0.29 0.35 0.48 0.79 0.58 0.02 0.22 0.05 0.13 0.33 0.08 0.47 0.45
PS9 0.33 0.03 0.37 0.32 0.32 0.53 0.55 0.83 0.68 0.05 0.34 0.07 0.27 0.12 0.11 0.29 0.22
PS10 0.37 0.09 0.42 0.41 0.53 0.68 0.74 0.85 0.85 0.08 0.47 0.25 0.40 0.31 0.18 0.57 0.53
SO2 0.26 0.24 0.07 0.24 0.00 0.07 0.07 0.03 0.06 0.56 0.07 0.09 0.36 0.01 0.05 0.02 0.01
SO4 0.10 0.10 0.11 0.04 0.07 0.06 0.07 0.05 0.03 0.77 0.06 0.16 0.57 0.13 0.02 0.08 0.03
SO5 0.11 0.12 0.17 0.02 0.13 0.12 0.05 0.04 0.10 0.77 0.11 0.07 0.53 0.00 0.02 0.00 0.00
SO7 0.21 0.17 0.10 0.21 0.08 0.12 0.16 0.14 0.15 0.57 0.01 0.11 0.45 0.18 0.09 0.34 0.31
SO8 0.10 0.09 0.10 0.07 0.29 0.16 0.20 0.14 0.23 0.61 0.22 0.07 0.31 0.09 0.06 0.03 0.03
SO10 0.34 0.13 0.11 0.27 0.19 0.12 0.22 0.27 0.24 0.76 0.18 0.12 0.71 0.16 0.01 0.26 0.25
SO1 0.41 0.02 0.33 0.37 0.61 0.37 0.32 0.32 0.48 0.11 0.82 0.09 0.45 0.33 0.17 0.33 0.39
SO3 0.42 0.02 0.37 0.39 0.49 0.42 0.44 0.51 0.55 0.02 0.71 0.26 0.48 0.40 0.09 0.49 0.51
SO6 0.41 0.14 0.32 0.39 0.56 0.27 0.24 0.26 0.39 0.04 0.76 0.10 0.47 0.16 0.18 0.22 0.24
SO9 0.28 0.03 0.26 0.27 0.43 0.25 0.24 0.22 0.33 0.02 0.74 0.10 0.47 0.07 0.04 0.17 0.14
SO11 0.07 0.15 0.15 0.02 0.06 0.26 0.14 0.15 0.19 0.06 0.18 1.00 0.36 0.15 0.13 0.39 0.33
CHD1 0.31 0.07 0.52 0.41 0.49 0.35 0.28 0.29 0.42 0.00 0.28 0.21 0.21 0.62 0.14 0.40 0.58
CHD2 0.21 0.14 0.32 0.29 0.34 0.19 0.23 0.20 0.28 0.10 0.30 0.19 0.30 0.71 0.01 0.35 0.58
CHD3 0.17 0.13 0.12 0.18 0.35 0.12 0.00 0.08 0.16 0.08 0.17 0.05 0.06 0.48 0.04 0.31 0.43
CHD4 0.22 0.24 0.18 0.27 0.26 0.17 0.04 0.21 0.20 0.04 0.17 0.02 0.14 0.78 0.10 0.33 0.61
CHD5 0.32 0.20 0.31 0.36 0.42 0.26 0.17 0.24 0.33 0.12 0.16 0.04 0.20 0.76 0.09 0.29 0.58
CHD6 0.30 0.11 0.24 0.30 0.30 0.27 0.18 0.26 0.30 0.01 0.15 0.09 0.11 0.78 0.13 0.34 0.63
CHD7 0.05 0.08 0.09 0.01 0.11 0.11 0.03 0.00 0.08 0.05 0.16 0.13 0.16 0.10 1.00 0.22 0.30
CHD8 0.00 0.07 0.16 0.05 0.26 0.27 0.16 0.21 0.27 0.03 0.28 0.32 0.21 0.24 0.15 0.57 0.49
CHD9 0.23 0.19 0.15 0.25 0.16 0.22 0.07 0.18 0.19 0.34 0.03 0.12 0.25 0.22 0.06 0.31 0.29
CHD10 0.09 0.15 0.27 0.21 0.38 0.42 0.41 0.45 0.50 0.07 0.27 0.26 0.17 0.45 0.11 0.67 0.65
CHD11 0.02 0.10 0.01 0.05 0.09 0.27 0.21 0.20 0.24 0.05 0.06 0.09 0.02 0.21 0.03 0.48 0.40
CHD12 0.04 0.10 0.03 0.07 0.11 0.20 0.14 0.15 0.19 0.19 0.08 0.11 0.21 0.04 0.21 0.48 0.34
CHD13 0.04 0.03 0.21 0.12 0.24 0.42 0.33 0.45 0.44 0.10 0.30 0.35 0.18 0.42 0.15 0.68 0.65
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Table 1 Correlation coefficients r among items and domains/facets of QLICD-CHD (n = 146) (Continued)
CHD14 0.00 0.04 0.13 0.04 0.13 0.25 0.20 0.32 0.28 0.04 0.10 0.52 0.20 0.34 0.10 0.51 0.49
CHD15 0.31 0.00 0.25 0.27 0.57 0.42 0.33 0.39 0.50 0.12 0.55 0.31 0.32 0.34 0.15 0.56 0.53
CHD16 0.22 0.07 0.00 0.10 0.03 0.08 0.12 0.16 0.12 0.55 0.20 0.02 0.54 0.06 0.13 0.37 0.27
The numbers in bold are aimed to show strong correlations between items and their own domains/facets easily. PHD: Physical domain, IND: Independence, AAS:
Appetite and Sleep, PHS: Physical Symptoms, PSD: Psychological domain, COG: Cognition, ANX: Anxiety, DEP: Depression, SEC: Self-Consciousness, SOD: Social
domain, SSS: Social Support/Security, SOE: Social Effects, SEF: Sexual Function, SPD: Specific domain, SYM: Symptom, EFM: Effect of medicine, EML: effect on
mental health and daily life.
Wan et al. Health and Quality of Life Outcomes 2014, 12:82 Page 5 of 11
http://www.hqlo.com/content/12/1/82reversely scored. Each domain score is obtained by add-
ing together the within-domain item scores. The overall
scale score is the sum of the four domain scores.
For comparison purposes, all domain scores were
linearly converted to a 0–100 scale using the formula:
SS = (RS-Min) × 100/R, where SS, RS, Min and R repre-
sent the standardized score, raw score, minimum score,
and range of scores, respectively.
Statistical analysis for psychometrics
The validity, reliability, and responsiveness of the QLICD-
CHD were analyzed. Validity is the degree to which the in-
strument measures what it is supposed to measure, with
several types of validity being distinguished [27,28]. Con-
struct validity was evaluated by Pearson’s correlation coef-
ficient r (item-domains/facets correlations) as well as by
factor analysis with Varimax Rotation. Multi-trait scaling
analysis [29] was employed to test item convergent and
disciminant validity, with the two criteria: (1) convergent
validity is supported when an item-domain correlation is
0.40 or greater; (2) disciminant validity is revealed when
item-domain correlation is higher than that with other
domains. Criterion-related validity was evaluated by
correlating corresponding domains of the QLICD-CHD
and SF-36 because of the lack of an agreed-upon gold
standard. Relatively high correlations among conceptually
related domains and relatively low correlation among
conceptually distinct domains would suggest high
criterion-related validity. And this can also demonstrate
convergent and discriminant validity because they in-
volve comparing logically related measures to see if they
are correlated more strongly (convergent) or more
weakly (discriminant).
Reliability is the degree to which an instrument is free
from random error, with being evaluated by measuring
internal consistency reliability and reproducibility fre-
quently. The internal consistency, which refers to the
homogeneity of the items of the scale, was assessed by
Cronbach’s alpha coefficient for each domain/facet. A
high internal consistency suggests that the scale is meas-
uring a single construct. Reproducibility (the test-retest
reliability) establishes the stability of an instrument over
time in a stable population [28]. It was evaluated by the
Pearson’s correlation coefficients between the first and
second assessments, and intra-class correlation (ICC)with definition of absolute for single measure under the
two-way mixed model [30,31]. Patients were considered
stable if they did not experience treatments the following
day to hospital.
Responsiveness is the instrument’s ability to detect
clinically important change over time. It was measured
by comparing the mean score change between the two
assessments before and after treatments using paired t-
tests as well as the effect size, SRM (standardized re-
sponse mean) [32,33].
Generalizability theory analysis
Besides classical test theory analysis above, we also ap-
plied Generalizability Theory (G theory) to investigate
the score dependability of the QLICD-CHD. G theory
has been presented as a way to refine the designs of
measurement procedures in an attempt to yield reliable
data [34-37]. Serving as an alternative to the more famil-
iar classical measurement theory, which yields the less
useful intra-class correlation coefficients, G theory ad-
dresses the dependability of measurements and allows
for the simultaneous estimation of multiple sources of
variance, including interactions. Thus, a distinction is
made between 2 types of studies: G studies and D stud-
ies. A G study quantifies the amount of variance associ-
ated with the different facets (factors) that are being
examined. A D study provides information about which
protocols are optimal for a particular measurement situ-
ation by generating Generalizability (G) coefficients that
can be interpreted as reliability coefficients across vari-
ous facets of the study.
In our research, G-Studies and D-Studies were per-
formed to estimate the variance components and de-
pendability coefficients in one facet person-by-item
design (p × i design). We defined the quality of life of pa-
tients as the target of measurement and items as one
facet of measurement error. Given every person is asked
to reply to all items, the design is One-facet Crossed De-
sign [34-37]. For the G-Study, a universe of admissible
observations, which consists of the object of measure-
ment and the measurement error facets, is defined and
the variance components are estimated. For the D-
Study, a universe of admissible generalizations, which
represents the measurement conditions based on the ob-
ject of measurement and the measurement facets a
Table 2 Correlation coefficients among domains scores of
QLICD-CHD and SF-36 (n = 146)
QLICD-CHD SF-36
PF RP BP GH VT SF RE MH
PHD 0.61 0.30 0.36 0.39 0.53 0.37 0.33 0.32
PSD 0.46 0.28 0.36 0.45 0.44 0.42 0.34 0.49
SOD 0.37 0.30 0.29 0.24 0.46 0.28 0.28 0.40
SPD 0.32 0.19 0.28 0.35 0.26 0.24 0.28 0.35
PHD: physical domain, PSD: psychological domain, SOD: social domain,
SPD: specific domain.
PF: physical function, RP: role-physical, BP: bodily pain, GH: general health,
VT: vitality, SF: social function, RE: role-emotional, MH: mental-health.
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the variance components associated with the universe of
admissible generalizations are estimated.
Results
Socio-demographic and clinical characteristics of the
sample
The 146 patients with CHD varied in age from 19 to 80,
with median age of 64.0 and mean age 62.1 ± 11.3.
Among the study patients, 132 (90.4%) were of Han eth-
nicity and others were of minority including Yi, Bai, Hui,
etc., the majority were married (128 cases, 87.7%) while
18 (12.3%) were single and others. On gender and edu-
cation level, 105 cases (71.9%) were male while 41
(28.1%) were female, 37 (25.3%) finished primary school,
while 75 (52.4%) completed high school, and 32 (22.0%)
had a college or post-graduate degree. Distribution of
occupations was as follow: workers 20.5% (30 cases),
farmer 9.6% (14), teacher 7.5% (11), cadre 19.9% (29),
and others 42.5% (62). With regard to perceived income,
20 (13.7%) were in poor, 93 (63.7%) in fair, and 33
(22.6%) in high. Regarding medical insurance, self-paid
accounted in 16 cases (11.0%) and partly public insurance/
public insurance accounted in 130 cases (89.0%). In terms
of clinical types, angina pectoris were 97 cases (67.4%)
while myocardial infarctions were 49 cases (32.6%).
Construct validity
Correlation analyses showed that there were strong asso-
ciations between items and their own domains/facets
(most correlation coefficients are higher than 0.5), but
weak relationship between items and other domains/
facets (see Table 1). For example, correlation coefficients
between PHD and items of PH1-PH8 (in bold) are
higher than those between PHD and other items. Espe-
cially, the correlation coefficients between items and
their own facets were much larger than that between
items and other facets.
There were 8 principal components (initial eigenvalues
>1) abstracted from 30 items of the general module
(QLICD-GM) by factor analysis, accounting for 68.1% of
the cumulative variance. By using the Varimax rotation
method, it can be seen that the 8 principal components
reflected different facets under three domains of the
general module. Specifically, the fourth and fifth princi-
pal components mainly represented the physical domain
with higher loadings on PH5(0.69), PH7(0.64) and PH8
(0.72); The second and third principal components
largely reflected the social domain with higher loadings
on SO1(0.76), SO4(0.78), SO5(0.83), SO6(0.76), SO8(0.62)
and SO10(0.83); The other principal components gener-
ally depicted the psychological domain with higher load-
ings on PS3(0.77), PS4(0.81), PS5(0.71), PS8(0.65), PS9
(0.69), PS10(0.80) and PS11(0.79).Similarly, the principal component factor analysis ex-
tracted 4 principal components from the 16 items of the
specific module with the cumulative variance of 60.6%,
reflecting 3 facets of this module. And here the first
principal component represented the facet of treatment
side-effects with higher factor loadings on CHD2(0.60),
CHD3(0.64), CHD4(0.83), CHD5(0.83) and CHD6(0.82),
the second and the fourth principal components cap-
tured the facet of mental and physical health with higher
factor loadings on CHD8(0.68), CHD9(0.65), CHD12(0.72),
CHD13(0.66), CHD15(0.70) and CHD16(0.66).
From results above, theoretical construct was confirmed
generally by data analysis, showing good construct validity.Criterion-related validity
Correlation coefficients among the domain scores of the
QLICD-CHD and SF-36 were presented in Table 2,
showing that the correlations between the same and
similar domains are generally higher than those between
different and non-similar domains. For example, the co-
efficient between the physical domain of QLICD-CHD
and physical function of SF-36 was 0.61, higher than any
other coefficients in this row. Similarly, the coefficient
between the psychological domain of QLICD-CHD and
mental health of SF-36 was 0.49, higher than any other
coefficients in this row (PCS and MCS are not mutually
exclusive domain of SF-36).
These confirmed the criterion-related validity to a rea-
sonable degree and also demonstrated the convergent
and divergent validity to some extent.Reliability
The reliability of the scale was evaluated by three proce-
dures: internal consistency, test-retest and ICC (see
Table 3 for details). The Cronbach's α for all domains
and facets were computed using the measurements data
at admission because of larger sample size. As can be
seen in Table 3, the Cronbach's α for these four domains
were higher than 0.70, and most of them were higher
than 0.70 at the facet levels.
Table 3 Reliability of the quality of life instrument QLICD-











Physical domain (PHD) 0.76 0.95 0.95 (0.91-0.97)
Independence 0.70 0.98 0.98 (0.97-0.99)
Appetite and sleep 0.46 0.77 0.77 (0.62-0.86)
Physical Symptoms 0.67 0.97 0.98 (0.96-0.99)
Psychological
domain (PSD)
0.90 0.92 0.92 (0.86-0.95)
Cognition 0.73 0.92 0.92 (0.87-0.96)
Anxiety 0.81 0.85 0.84 (0.74-0.91)
Depression 0.84 0.93 0.93 (0.88-0.96)
Self-consciousness 0.76 0.91 0.91 (0.84-0.95)
Social domain (SOD) 0.63 0.86 0.85 (0.75-0.91)
Social Support/Security 0.74 0.84 0.83 (0.71-0.90)
Social Effects 0.75 0.92 0.91 (0.85-0.95)
Sexual function - 0.94 0.96 (0.94-0.98)
Sub-total (QLICD-GM) - 0.92 0.92 (0.86-0.95)
Specific domain (SPD) 0.79 0.80 0.80 (0.68-0.88)
Symptom 0.78 0.70 0.72 (0.54-0.73)
Effect of medicine - 0.61 0.61 (0.40-0.76)
Effect on mental
health and daily life
0.65 0.89 0.92 (0.86-0.95)
Total (TOT) - 0.90 0.91 (0.84-0.95)
- not acceptable/suitable, ICC: intra-class correlation, CI: confidence interval.
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mains and 13 facets of QLICD-CHD ranged between
0.61-0.98, with r = 0.90 for the overall scale and the
minimum r = 0.80 for SPD among the four exclusive do-
mains. The differences in domain and facet scores be-
tween the first and the second assessments were not
statistically significant for all domains and most facets
except for Independence and symptom by paired t tests
(P > 0.05). The results from ICC were very similar to
Pearson’s correlation coefficients (r).Table 4 The estimated variance components and percentage
quality of life instrument QLICP-CHD
p(person) i(item)
Domain Variance component Percent (%) Variance com
PHD 0.50 28.30 0.08
PSD 0.59 42.20 0.15
SOD 0.21 11.76 0.25
SPD 0.26 17.45 0.16
p: person effect, i: item effect, p × i: person-by-item interaction effect.Reliability from generalizability theory
The estimated G-study results were provided in Table 4
based on the current design, in which 146 patients filled
out the quality of life instrument QLICD-CHD with 46
items. For physical domain, the variances accounted for
67.22% by person-by-item interactions and 28.30% by
person, only a small source of variation (4.48%) was due
to item. Given the largest source of variation in this do-
main score is by the person-by-item interaction, it
means that different people might understand and react
to the same item in different ways despite having the
same total score on the scale. Similarly, the largest
source of variation was due to person-by-item interac-
tions in other domains, while the variances by person
were in the second place (except for social domain by
item).
The D-Studies were performed to estimate G-coefficients
and Ф coefficients for the current design and alternative
designs with varied numbers of items for four domains of
QLICP-CHD, with results presenting in Table 5. It showed
acceptable reliability coefficients (G and Ф coefficients
>0.70) for three of four domains except for social domain
for the current design. In addition, Table 5 showed the ef-
fects of the various levels of items (from 6 to 22) on reli-
ability with G ranging from 0.59 to 0.92, and Ф ranging
from 0.55 to 0.91.Responsiveness
It can be seen in Table 6 that significant changes oc-
curred for domains of physical, psychological and the
specific, and also the sub-total (QLICD-GM) and overall
scale (P < 0.01) with effect size SRM ranging from 0.32
to 0.67. At the facets level, five of thirteen facets were of
statistical significance with effect size SRM ranging from
0.20 to 0.88.Discussions
On development approach and advantages
Since same-class diseases such as cancers share many
things in common, an approach widely adopted in recent
years to develop QOL instruments for diseases within aof variance for p × i design in G-study for four domains of
p * i(person*item)





Table 5 G-coefficients and Ф-coefficients for different numbers of items for p × I design in D-study for four domains of
quality of life instrument QLICP-CHD
Domain Number of items σ2(P) σ2(I) σ2(PI) σ2(δ) σ2(Δ) σ2(×PI) σ
2(Eρ2) Φ
Physical domain 6 0.51 0.01 0.20 0.20 0.21 0.02 0.72 0.70
8 0.51 0.01 0.15 0.15 0.16 0.02 0.77 0.76
10 0.51 0.01 0.12 0.12 0.13 0.01 0.81 0.80
12 0.51 0.01 0.10 0.10 0.11 0.01 0.84 0.83
14 0.51 0.01 0.09 0.09 0.09 0.01 0.86 0.85
Psychological domain 9 0.59 0.02 0.07 0.07 0.09 0.02 0.89 0.87
10 0.59 0.02 0.07 0.07 0.08 0.02 0.90 0.88
11 0.59 0.01 0.06 0.06 0.07 0.02 0.91 0.89
12 0.59 0.01 0.06 0.06 0.07 0.02 0.92 0.90
13 0.59 0.01 0.05 0.05 0.06 0.02 0.92 0.91
Social domain 9 0.21 0.03 0.14 0.14 0.17 0.03 0.59 0.55
11 0.21 0.02 0.12 0.12 0.14 0.03 0.64 0.60
13 0.21 0.02 0.10 0.10 0.12 0.02 0.67 0.63
15 0.21 0.02 0.09 0.09 0.10 0.02 0.71 0.67
17 0.21 0.02 0.08 0.08 0.09 0.02 0.73 0.70
Specific domain 14 0.26 0.01 0.08 0.08 0.09 0.01 0.77 0.75
16 0.26 0.01 0.07 0.07 0.08 0.01 0.80 0.77
18 0.26 0.01 0.06 0.06 0.07 0.01 0.81 0.79
20 0.26 0.01 0.05 0.05 0.06 0.01 0.83 0.81
22 0.26 0.01 0.05 0.05 0.06 0.01 0.84 0.82
σ2(δ) is the variance components of relative error.
σ2(Δ) is the variance components of absolute error.
σ2(×PI) is the variance components of error when estimating the universe score by using sample mean.
σ2(Eρ2) is the Generalizability coefficient.
Φ is the index of dependability.
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tire class of disease with specific modules for individual
diseases to capture both common features within the dis-
ease class and disparities among different disease mem-
bers. This approach can substantially reduce the amount
of time and effort in developing new instruments. Both
the QLQs from EORTC and the FACTs from CORE for
QOL assessments of cancer patients have been developed
based on this modular principle [21,38]. Unlike these two
QOL instruments systems, we employed this modular
approach to systematically and more efficiently develop
a system of new instruments for chronic diseases dir-
ectly, with QLICD-GM forming the general module and
QLCID-CHD being a specific scale for coronary heart dis-
ease. This modular approach unifies all disease-specific in-
struments of QLICDs using the same general module with
similar constructs. To our knowledge, although a number
of instruments have been widely used for studying CHD
impacts on patients’ QOL, no one was developed directly
by the modular approach. Therefore, the QLICD-CHD
has several advantages over existing instruments [23,24].
First, it can compare HRQOL across diseases by thegeneral module and also capture the symptoms and side
effects by the specific module, demonstrating both generic
and specific properties. Second, it consists of a moderate
number of items with a clear hierarchical structure
(items→ facets→ domains→ overall) so that mean scores
can be computed not only at the domain (four domains)
and the overall levels but also at the different facet levels
(13 facets) to detect changes in greater detail. Users can
select either one or both levels for a study at hand. Third
and perhaps more important is the strong Chinese cul-
tural background underlying the QLICD-CHD. For ex-
ample, the Chinese culture pays more attention to family
relationship and kinship, dietary, temperament and high
spirit, which are probed by the items of QLICD-CHD fo-
cusing on this type of cultural heritage such as appetite,
sleep, energy and family support. Specifically, items of
PH6 ‘Have you had a good appetite?’, PH7 ‘Were you satis-
fied with your sleep?’, PH2 ‘Have you felt fatigue easily?’,
SO4 ‘Have you had good relations with your families?’, and
SO5 ‘Could you acquire material and emotional help and
support from your family when you need?’ etc. reflected
these aspects in details.
Table 6 Responsiveness of the quality of life instrument QLICD-CHD (xs) (n = 111)
Domains/Facets Before treatment After treatment Differences SRM t p
Physical domain 53.60 ± 20.37 58.87 ± 17.72 -5.26 ± 12.46 0.42 -4.45 0.000
Independence 60.51 ± 28.49 64.49 ± 26.03 -3.98 ± 18.42 0.22 -2.28 0.025
Appetite and Sleep 46.62 ± 25.61 50.45 ± 23.83 -3.83 ± 23.04 0.17 -1.75 0.083
Physical Symptoms 51.35 ± 23.69 58.86 ± 19.92 -7.51 ± 14.82 0.51 -5.34 0.000
Psychological domain 70.52 ± 20.51 75.63 ± 17.78 -5.12 ± 16.20 0.32 -3.33 0.001
Cognition 57.55 ± 28.96 63.74 ± 28.50 -6.19 ± 19.79 0.31 -3.30 0.001
Anxiety 63.81 ± 25.16 72.22 ± 20.11 -8.41 ± 20.21 0.42 -4.38 0.000
Depression 78.23 ± 23.52 82.21 ± 18.95 -3.98 ± 19.78 0.20 -2.12 0.036
Self-Consciousness 78.15 ± 22.22 80.41 ± 20.43 -2.25 ± 18.50 0.12 -1.28 0.202
Social domain 62.29 ± 14.48 62.18 ± 14.50 0.10 ± 8.36 0.01 0.13 0.898
Social Support/Security 68.73 ± 20.20 69.71 ± 19.51 -0.98 ± 13.98 0.07 -0.74 0.464
Social Effects 53.83 ± 24.24 52.48 ± 24.41 1.35 ± 16.63 0.08 0.86 0.394
Sexual Function 57.43 ± 31.00 55.86 ± 32.33 1.58 ± 21.13 0.07 0.79 0.433
Sub-total (QLICD-GM) 62.99 ± 14.56 66.23 ± 13.50 -3.24 ± 9.61 0.34 -3.55 0.001
Specific domain 61.51 ± 14.00 70.12 ± 13.32 -8.60 ± 12.91 0.67 -7.02 0.000
Symptom 64.90 ± 18.96 84.27 ± 19.27 -19.37 ± 22.00 0.88 -9.27 0.000
Effect of medicine 47.30 ± 23.92 60.59 ± 31.18 -13.29 ± 32.83 0.40 -4.27 0.000
Effect on mental health and daily life 60.84 ± 15.38 61.74 ± 14.40 -0.90 ± 11.95 0.08 -0.79 0.429
Total (TOT) 62.48 ± 13.22 67.58 ± 12.27 -5.11 ± 9.50 0.54 -5.67 0.000
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Generally, a practical QOL instrument must be validated
with respect to at least three aspects: validity, reliability
and responsiveness. Instrument validity is the extent to
which an instrument can capture what it purports to
measure. By following WHO’s definition of QOL and
the programmed decision procedures, we developed the
QLICD-CHD by using focus group discussion, in-depth
interview and pre-testing to effectively reduce the num-
ber of items in the final version to 30 from an initial 73
item pool for the general module, and to 16 from an ini-
tial pool of 25 items for the specific module, ensuring
good content validity and sound conceptual structure.
Correlation analyses showed strong association between
items and their own domains/facets but weak correla-
tions between items and other domains/facets. Factor
analysis revealed that the components extracted from
the data basically coincide with the theoretical construct
of the instrument. These results confirmed the good
construct validity. Correlation coefficients between do-
main scores of QLICD-CHD and SF-36 showed the
criterion-related validity to a reasonable degree and the
convergent and divergent validity to some extent.
Reliability refers to the reproducibility or consistency of
item scores from one assessment to another. Test-retest
reliability (r), ICC and internal consistency (Cronbach’s α)
are the most frequently used indicators and were tested in
the current study. It is well recognized that internalconsistency (α) should be at least 0.70 and reliability (r)
should be above 0.80 in a test–retest situation [32]. Thus,
our results in Table 3 showed that this instrument has
good reliability for all α were higher than 0.70 and r (ICC)
greater than 0.80 at domain levels.
The assessment methods on responsiveness can be gen-
erally divided into two categories: internal and external
[32,33]. In this paper we focused on internal responsive-
ness with the hypothesis that the sensitive instrument
should detect changes when they occur after treatment.
SRM is a good indicator of effect size, with values of 0.20,
0.50 and 0.80 representing small, moderate and large re-
sponsiveness [32,33]. As seen from Table 6, QOL scores
had significant changes after treatment for three of the
four domains as well as the overall score (P < 0.05), with
SRM equal to 0.52, 0.28, 0.62 and 0.56. Given that it rea-
sonable to expect no statistically significant change for
the social domain and some facets pertaining to stable
traits post-treatment, QLICD-CHD seems to have good
responsiveness.
On analysis of generalizability theory
Traditionally, the scale is assessed by classical test theory
analysis, in this research Generalizability Theory was
also applied both in G-study and D-study. Which coeffi-
cients will be selected depending on the researchers’ in-
terests? If one’s interest lies in ranking people (relative
decision), then the G-coefficient informs about how
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lute standings to a criterion (absolute decision), the
index of dependability Ф reflects the score dependability.
The index of dependability is typically lower than G-
coefficients because they consider the main error effects
in addition to the interaction effects that are used for G-
coefficients. This research presented both G-coefficients
and Ф, and also their changes when items assumed to
be changed. For social domain, we estimated a G-
coefficient of 0.64 and an index of dependability of 0.60
for the current design, which was a little below the ac-
ceptable level of 0.70. Hence, the domain’s items need
improvement. For an alternative design with 17 items,
the G-coefficient estimated to be 0.74 and the index of
dependability 0.70. Therefore, it will be better to increase
the numbers of items of social domain from 11 to 17 in
order to reach an acceptable dependability. For other do-
mains, G- coefficients and index of dependability were
all greater than 0.70 for the current design, and changed
a little as items changing. It can be considered that
current items are reasonable and acceptable for these
domains.
To sum up, the analysis from Generalizability Theory
confirmed the reliability of the scale further. However,
the numbers of items for social domain should be in-
creased in order to obtain better reliability.Study limitations
It is worthy to note that the sample size of the study is
not very large, which may also affect the findings, espe-
cially those with respect to factor analysis (146 cases vs
30 variables for the general module). Although correl-
ational analysis was conducted simultaneously to display
the construct, which overcome it to some extent, add-
itional larger studies are needed to validate it further.
Moreover, the subjects in this study were selected from
the inpatient population at hospitals. Additional studies
are needed to assess the generalizability of the instru-
ment to other settings and populations such as outpa-
tients at a local clinic.
In summary, the QLICD-CHD can be used as a useful
instrument in measuring and assessing quality of life for
patients with coronary heart disease who speak Chinese
(the largest population in the world), with good psycho-
logical properties and some highlights.
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